420
Views
14
CrossRef citations to date
0
Altmetric
Letter to the Editor

Antimicrobial in vitro activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa – a pilot Bulgarian study

, , , &
Pages 870-873 | Received 26 Jul 2019, Accepted 02 Aug 2019, Published online: 21 Aug 2019

References

  • Zavascki AP, Carvalhaes CG, Picão RC, et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther. 2010;8:71–93.
  • Stokowski LA, Solomon SL. Antimicrobial resistance: The big picture. Medscape & CDC: September 16, 2013. Available from: https://www.medscape.com/viewarticle/810801.
  • Brooks M. “Chilling” data on antibiotic resistant infections in US hospital patients. Medscape Medical News: March 03, 2016. Available from: https://www.medscape.com/viewarticle/859829.
  • Avery LM, Nicolau DP. Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Expert Opin Investig Drugs. 2018;27:325–338.
  • Bandali A, Bias TE. Trimethoprim-sulfamethoxazole for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections. Infect Dis (Lond). 2019;51:456–458.
  • Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23:704–712.
  • Sader HS, Castanheira M, Flamm RK, et al. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents. 2015;46:53–59.
  • Sader HS, Castanheira M, Shortridge D, et al. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016. Antimicrob Agents Chemother. 2017;61:pii: e01045-17.
  • Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs. 2018;78:65–98.
  • Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011;66:48–53.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.